Envestnet Asset Management’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.3M | Sell |
88,755
-21,341
| -19% | -$316K | ﹤0.01% | 3455 |
|
|
2026
Q1 | $1.6M | Sell |
110,096
-7,800
| -7% | -$90.5K | ﹤0.01% | 3158 |
|
|
2025
Q4 | $1.13M | Sell |
117,896
-12,913
| -10% | -$124K | ﹤0.01% | 3195 |
|
|
2025
Q3 | $1.23M | Buy |
130,809
+9,422
| +8% | +$90K | ﹤0.01% | 3214 |
|
|
2025
Q2 | $1.28M | Buy |
121,387
+25,753
| +27% | +$325K | ﹤0.01% | 3117 |
|
|
2025
Q1 | $1.44M | Buy |
95,634
+26,557
| +38% | +$442K | ﹤0.01% | 2955 |
|
|
2024
Q4 | $1.14M | Sell |
69,077
-1,042
| -1% | -$20.6K | ﹤0.01% | 3086 |
|
|
2024
Q3 | $1.73M | Sell |
70,119
-5,833
| -8% | -$151K | ﹤0.01% | 2761 |
|
|
2024
Q2 | $1.92M | Buy |
75,952
+212
| +0.3% | +$5.49K | ﹤0.01% | 2621 |
|
|
2024
Q1 | $1.92M | Sell |
75,740
-2,160
| -3% | -$52.3K | ﹤0.01% | 2599 |
|
|
2023
Q4 | $1.77M | Buy |
77,900
+1,898
| +2% | +$39.3K | ﹤0.01% | 2549 |
|
|
2023
Q3 | $1.42M | Buy |
+76,002
| New | +$1.58M | ﹤0.01% | 2564 |
|
|
2022
Q4 | – | Sell |
-13,844
| Closed | -$329K | – | 3947 |
|
|
2022
Q3 | $329K | Buy |
13,844
+3,999
| +41% | +$92K | ﹤0.01% | 3282 |
|
|
2022
Q2 | $220K | Buy |
+9,845
| New | +$220K | ﹤0.01% | 3530 |
|
|
2021
Q1 | – | Sell |
-30,125
| Closed | -$1.36M | – | 3496 |
|
|
2020
Q4 | $1.36M | Buy |
30,125
+3,460
| +13% | +$131K | ﹤0.01% | 2003 |
|
|
2020
Q3 | $944K | Buy |
26,665
+4,533
| +20% | +$164K | ﹤0.01% | 2048 |
|
|
2020
Q2 | $835K | Buy |
22,132
+1,328
| +6% | +$43.8K | ﹤0.01% | 2073 |
|
|
2020
Q1 | $601K | Buy |
20,804
+1,453
| +8% | +$58.8K | ﹤0.01% | 2111 |
|
|
2019
Q4 | $1M | Buy |
19,351
+1,979
| +11% | +$115K | ﹤0.01% | 2023 |
|
|
2019
Q3 | $954K | Sell |
17,372
-1,510
| -8% | -$77.5K | ﹤0.01% | 1971 |
|
|
2019
Q2 | $767K | Buy |
18,882
+1,173
| +7% | +$42.8K | ﹤0.01% | 2125 |
|
|
2019
Q1 | $536K | Buy |
17,709
+6,227
| +54% | +$213K | ﹤0.01% | 2311 |
|
|
2018
Q4 | $386K | Buy |
+11,482
| New | +$414K | ﹤0.01% | 2293 |
|
|
2018
Q3 | – | Sell |
-950
| Closed | -$30K | – | 1303 |
|
|
2018
Q2 | $30K | Sell |
950
-2,607
| -73% | -$107K | ﹤0.01% | 2335 |
|
|
2018
Q1 | $173K | Sell |
3,557
-1,406
| -28% | -$79.4K | ﹤0.01% | 1663 |
|
|
2017
Q4 | $267K | Buy |
4,963
+12
| +0.2% | +$664 | ﹤0.01% | 1722 |
|
|
2017
Q3 | $287K | Buy |
4,951
+334
| +7% | +$17.5K | ﹤0.01% | 1689 |
|
|
2017
Q2 | $228K | Sell |
4,617
-73
| -2% | -$3.36K | ﹤0.01% | 1826 |
|
|
2017
Q1 | $204K | Buy |
+4,690
| New | +$224K | ﹤0.01% | 1911 |
|
|
2016
Q1 | – | Sell |
-4,451
| Closed | -$170K | – | 3079 |
|
|
2015
Q4 | $170K | Buy |
4,451
+731
| +20% | +$28K | ﹤0.01% | 2114 |
|
|
2015
Q3 | $118K | Buy |
+3,720
| New | +$130K | ﹤0.01% | 2268 |
|
Other funds holding ANIK
CM
IP
CWP
RS
NCM
SO
Envestnet Asset Management's ANIK Position: Q2 2026 in Review
Envestnet Asset Management reduced its Anika Therapeutics (ANIK) stake by 19% in Q2 2026, selling an estimated $316K and leaving 88,755 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3455.
Envestnet Asset Management first reported a position in ANIK in Q3 2015 and has held it in 31 quarters since. The position peaked at $1.92M in Q2 2024. 31 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.
- Envestnet Asset Management held 88,755 shares of Anika Therapeutics worth $1.3M as of Q2 2026.
- Envestnet Asset Management sold 21,341 Anika Therapeutics shares in Q2 2026, an estimated $316K.
- Anika Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3455 holding.
- Envestnet Asset Management first reported a position in Anika Therapeutics in Q3 2015 and has held it in 31 quarters since.
- Envestnet Asset Management's Anika Therapeutics position peaked at $1.92M in Q2 2024.
- 31 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.
Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.